Señales en vivo de TRVI | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions...

Stats
Volumen de hoy	26 782.00
Volumen promedio	309 826
Capitalización de mercado	208.26M
EPS	$0 ( 2024-03-20 )
Próxima fecha de ganancias	( $-0.0900 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.41
ATR14	$0.0190 (0.63%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-15	Galletta Christopher	Buy	28 500	Stock Option (right to buy)
2024-02-15	Simon Farrell	Buy	175 000	Stock Option (right to buy)
2024-02-15	Clark David J	Buy	175 000	Stock Option (right to buy)
2024-02-15	Good Jennifer L	Buy	630 000	Stock Option (right to buy)
2024-02-15	Sciascia Thomas	Buy	150 000	Stock Option (right to buy)

INSIDER POWER
78.91
Last 98 transactions
Buy: 31 017 280 \| Sell: 1 379 035

Volumen Correlación

Largo: 0.11 (neutral)

Corto: 0.84 (strong)

Signal:(50.831) Same movement expected

Trevi Therapeutics Inc Correlación

10 Correlaciones Más Positivas
HAPP	0.964
ADSE	0.959
CRTO	0.957
TXRH	0.956
EQ	0.952
KRTX	0.951
AIHS	0.949
MEDP	0.949
KBAL	0.948
TA	0.948

10 Correlaciones Más Negativas
CYAN	-0.955
WTER	-0.954
DCRC	-0.954
SSRM	-0.952
BIOL	-0.947
WISA	-0.94
CYXT	-0.939
UTMD	-0.938
IMKTA	-0.928
PYR	-0.926

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Trevi Therapeutics Inc Correlación - Moneda/Commodity

-0.06
( neutral )

-0.51
( weak negative )

0.00
( neutral )

-0.32
( neutral )

0.31
( neutral )

-0.26
( neutral )

Trevi Therapeutics Inc Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-43 000.00 (0.00 %)
EPS:	$-0.450

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.830

Financial Reports:

No articles found.

Trevi Therapeutics Inc

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Actualizaciones en tiempo real para Trevi Therapeutics Inc [TRVI]

Upcoming Earnings Alert